ADHD Drugs Show Promise for Menopausal Brain Fog
A new scoping review finds ADHD medications may help improve self-reported executive function during the menopause transition.
Updated on Oct. 20, 2026 in Alzheimer’s
Live Poll
Would you consider taking medication to help manage brain fog during the menopause transition?
A scoping review evaluated the use of lisdexamfetamine and atomoxetine to address cognitive challenges in perimenopausal women. Results indicate that these medications improved self-reported executive function scores while having little impact on objective cognitive tests.
Why it matters
Estrogen fluctuations during the menopause transition disrupt signaling in the prefrontal cortex, leading to cognitive issues for many. This research explores whether ADHD medications could serve as a potential therapy for this executive dysfunction.
The study analyzed women aged 45 to 60 whose last menstrual period occurred within the last 10 years. While 44% to 60% of women report perimenopausal cognitive changes, no pharmacological interventions are currently FDA-approved for this condition.
The players
The Menopause Society
This organization serves as a leading resource for medical professionals and the public regarding menopause-related health and research.
The details
Researchers evaluated executive function by comparing total Brown Attention Deficit Disorder Scale scores against placebo-treated participants. While self-reported findings showed improvement, neuroimaging data from a subset of women taking lisdexamfetamine provided additional support for these results.
Timeline
October 20-24, 2026, marks the presentation of study findings at the Annual Meeting of The Menopause Society.
The Big Picture
This study adapts the use of the Brown Attention Deficit Disorder Scale to measure executive function outcomes within a new patient demographic. The findings suggest a potential pivot in how clinicians may address symptoms of cognitive decline during the menopause transition.
Women experiencing perimenopausal cognitive changes currently lack specific FDA-approved pharmacological interventions. These findings suggest that discussions with healthcare providers about medication options could become a more viable path for managing brain fog.
The takeaway
While ADHD medications show potential for improving perceived executive function, they did not significantly alter objective measures like working memory. Patients should consult their doctors to determine if existing pharmaceutical options align with their specific health needs.
What happens next
Findings from the review will be formally presented during the Annual Meeting of The Menopause Society in San Diego from October 20-24, 2026.
Further reading
For more context on cognitive health during midlife, visit the Alzheimer’s section.
Live Poll
Would you consider taking medication to help manage brain fog during the menopause transition?
